SEARCH

SEARCH BY CITATION

References

  • 1
    United States Food and Drug Administration. FDA Approves Latuda to Treat Schizophrenia in Adults. Press release, 28 October 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm (accessed 28 October 2010).
  • 2
    Sunovion. Latuda (lurasidone HCl) Tablets Prescribing Information. http://www.latuda.com/LatudaPrescribingInformation.pdf (accessed 28 October 2010).
  • 3
    Nakamura M, Ogasa M, Guarino J et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 82936.
  • 4
    Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334: 17181.
  • 5
    Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18: 171526.
  • 6
    Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010; 11: 80212.
  • 7
    Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008; 186: 197207.
  • 8
    Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007; 572: 16070.
  • 9
    Loebel A, Cucchiaro J, Kalali A, Daniel D, Siu C. Detection of drug-placebo difference in schizophrenia clinical trials: site-related factors. Schizophr Res 2010; 117: 501. Abstract.
  • 10
    Cucchiaro J, Silva R, Ogasa M et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled pearl 2 trial. Schizophr Res 2010; 117: 493. Abstract.
  • 11
    Ereshefsky L, Jhee S, Phillips D et al. Assessment of the maximum tolerated dose (MTD) of lurasidone in patients with schizophrenia. Schizophr Res 2010; 117: 3812. Abstract.
  • 12
    Harvey PD, Murasaki M, Cucchiaro J, Ogasa M, Loebel A. A three arm dose finding study of lurasidone: efficacy and tolerability data. Schizophr Res 2010; 117: 3745. Abstract.
  • 13
    Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder SR. Efficacy of lurasidone in schizophrenia: results of a pooled analysis based on a 5-factor model of schizophrenia. Schizophr Res 2010; 117: 267. Abstract.
  • 14
    Cucchiaro J, Pikalov A, Ogasa M et al. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol 2010; 13 (Suppl. 1): 217. Abstract.
  • 15
    Loebel A, Cucchiaro J, Ogasa M et al. Efficacy of lurasidone in schizophrenia: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010; 13 (Suppl. 1): 2278. Abstract.
  • 16
    Cucchiaro J, Potkin SG, Ogasa M, Loebel A. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull 2009; 35 (Suppl. 1): 3423. Abstract. Poster also presented as Potkin SG, Cucchiaro J, Ogasa M, Loebel A. NCDEU Meeting, Hollywood, Florida, 29 June–2 July 2009, and as Potkin SG, Ogasa M, Cucchiaro J, Loebel A. American College of Neuropsychopharmacology Meeting, Scottsdale, Arizona, 7–11 December 2008.
  • 17
    Ogasa M, Loebel A, Cucchiaro J et al. Effect of lurasidone on depressive symptoms in patients with schizophrenia. Schizophr Bull 2009; 35 (Suppl. 1): 3445. Abstract.
  • 18
    Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe R. Performance and interview-based assessments of cognitive change in a randomised, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Bull 2009; 35 (Suppl. 1): 357. Abstract.
  • 19
    Guarino J, Loebel A, Cucchiaro J, Ogasa M, Silva R, Siu C. Lurasidone for schizophrenia: symptomatic remission during short-term treatment. Schizophr Bull 2009; 35 (Suppl. 1): 373. Abstract.
  • 20
    Ogasa M, Severs J, Phillips D, Guarino J, Tamura N, Nakamura M. Safety of lurasidone in schizophrenia: results of a phase 2, placebo-controlled, study. Schizophr Bull 2007; 33: 571. Abstract.
  • 21
    Phillips D, Ogasa M, Severs J, Nakamura M, Guarino J, Tamura N. Efficacy of lurasidone in schizophrenia: results of a phase 2, placebo-controlled, study. Schizophr Bull 2007; 33: 5723. Abstract.
  • 22
    Ogasa M, Boylan M, Phillips D, Srivastava A, Tamura N, Guarino J. Efficacy of lurasidone (SM-13496) in the treatment of schizophrenia: results of two, phase 2, placebo-controlled studies. Eur Neuropsychopharmacol 2005; 15: S5223. Abstract.
  • 23
    Ishiyama T, Loebel A, Cucchiaro J et al. Comparative receptor binding profile of lurasidone and other first and second generation antipsychotics. Int J Neuropsychopharmacol 2010; 13 (Suppl. 1): 222. Abstract.
  • 24
    Cole P, Serradell N, Rosa E, Bolos J. Lurasidone hydrochloride. Dopamine D2/5-HT2A antagonist, treatment of schizophrenia. Drugs Future 2008; 33: 31622.
  • 25
    Dainippon Sumitomo Pharma. Lurasidone Meeting June 12, 2009 Presentation Slides. http://www.ds-pharma.com/ir/presentation/img/rd.2009.06.pdf (accessed 13 October 2010).
  • 26
    Sunovion. Lurasidone Demonstrated Efficacy in Treating Patients with Schizophrenia in Pivotal Phase 3 Study. Press release. http://www.sunovion.com/news/pressReleases-dspa/20090826.pdf (accessed 27 October 2010).
  • 27
    Dainippon Sumitomo Pharma. Second Quarter Financial Results for FY2010 (Apr. 1 to Sep. 30, 2010). Presentation 2 November 2010. http://www.ds-pharma.com/pdf_view.php?id=55 (accessed 2 November 2010).
  • 28
    Horisawa T, Tokuda K, Ishibashi T, Ogasa M, Silva R. Receptor binding profile of lurasidone: a novel psychotropic agent under development for schizophrenia and bipolar disorder. Poster presented at the American College of Neuropsychopharmacology, Hollywood, Florida, 6–10 December 2009.
  • 29
    Nasrallah HA, Cucchiaro J, Hsu J, Silva R, Loebel A. Metabolic effects of lurasidone: results from Pearl 1, a double-blind, placebo-controlled 6-week trial in schizophrenia. Poster presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, 6–10 December 2009.
  • 30
    Cucchiaro J, Loebel A, Silva R, Philips D, Ogasa M, Xu J. Efficacy and safety of lurasidone in phase 2/3 acute schizophrenia trials. Poster presented at the NCDEU Meeting, Hollywood, Florida, 29 June–2 July 2009.
  • 31
    Horisawa T, Tokuda K, Ogasa M, Ishibashi T. Receptor binding profile of lurasidone: a novel psychotropic agent under development for schizophrenia and bipolar disorder. Poster presented at the NCDEU Meeting, Hollywood, Florida, 29 June–2 July 2009.
  • 32
    Loebel A, Cucchiaro J, Ogasa M et al. Efficacy of lurasidone: summary of results from the clinical development program. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14–17 June 2010.
  • 33
    Preskorn S, Chiu YY, Sarubbi D, Ogasa M, Cucchiaro J, Loebel A. Lurasidone pharmacokinetics: assessment of potential drug-drug interactions. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14–17 June 2010.
  • 34
    Chiu YY, Preskorn S, Sarubbi D, Cucchiaro J, Loebel A. Effect of food on lurasidone absorption. Poster presented at the NCDEU Meeting, Boca Raton, Florida, 14–17 June 2010.
  • 35
    Citrome L. Show me the evidence: using number needed to treat. South Med J 2007; 100: 8814.
  • 36
    Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008; 117: 4129.
  • 37
    Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009; 4: 22937.
  • 38
    Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 9906.
  • 39
    Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007; 149: 192202.
  • 40
    Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr 2004; 9 (Suppl. 11): 614.
  • 41
    Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 51926.
  • 42
    Citrome L. Using ziprasidone effectively: the food effect and dose-response. Adv Ther 2009; 26: 73948.
  • 43
    Gandelman K, Alderman JA, Glue P et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry 2009; 70: 5862.
  • 44
    Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008; 8: 107991.
  • 45
    Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122(July): 3948.
  • 46
    Citrome L. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? Int J Clin Pract 2010; 64: 14625.
  • 47
    Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010; 64: 70718.
  • 48
    Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007; 13: 13777.
  • 49
    Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006; 2: 42743.
  • 50
    Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009; 63: 123748.
  • 51
    Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009; 63: 176284.
  • 52
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
  • 53
    Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 15263.
  • 54
    Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14: 42947.
  • 55
    Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009; 10: 191728.